New Long-Acting Biologic Advances Care for Severe Asthma
A newly approved antibody therapy targets eosinophilic inflammation in asthma and nasal polyps with infrequent dosing and strong phase 3 evidence.
A long-acting biologic antibody, depemokimab, has received a positive recommendation from European regulators for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, showing meaningful reductions in exacerbations and symptom burden when added to standard therapy.
Study Details
Severe eosinophilic asthma and chronic rhinosinusitis with…
